From shutdown shock to whiplash rehires: setting the stage What looked like routine shutdown turbulence turned into a case study in whiplash staffing, as 954 laid-off Health and Human Services employees were reinstated with back pay by Nov. 21 following testimony from Thomas Nagy Jr. that confirmed
The IRA’s negotiation era comes into focus: why the 2027 price list matters now Sudden, double-digit cuts to high-spend drugs concentrate attention fast, and the newly finalized 2027 Medicare prices did exactly that by signaling roughly $12 billion in backcast savings if applied to 2024 use and an
James Maitland has spent his career stitching together robotics, sensors, and cloud intelligence to solve real problems at the bedside. That blend of hands‑on engineering and clinical pragmatism shows up in how he talks about seizure detection for the most fragile patients—newborns, including
I'm thrilled to sit down with James Maitland, a seasoned expert in healthcare policy and pharmaceutical regulation, with a deep focus on the complex world of pharmacy benefit managers (PBMs) and drug pricing reforms in the United States. With years of experience analyzing the intricacies of the
As the deadline for the enhanced Affordable Care Act (ACA) subsidies looms on December 31, 2025, a staggering 4 million Americans stand at risk of losing health coverage, with millions more facing steep premium hikes, sparking intense debate across political aisles, policy circles, and among
As we dive into the critical topic of healthcare funding, I'm thrilled to speak with James Maitland, a seasoned expert in healthcare policy and hospital finance. With years of experience analyzing the intricacies of Medicaid funding and the operational challenges faced by safety-net hospitals,
